An eight-week, double-blind, group-sequential design, placebo controlled trial to evaluate the safety and efficacy of the co- administration of sertraline and elzasonan (CP-448,187) in outpatients with major depressive disorder

Trial Profile

An eight-week, double-blind, group-sequential design, placebo controlled trial to evaluate the safety and efficacy of the co- administration of sertraline and elzasonan (CP-448,187) in outpatients with major depressive disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Elzasonan; Sertraline
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Nov 2008 Actual patient number (262) added as reported by ClinicalTrials.gov.
    • 16 Aug 2007 Status changed from recruiting to completed
    • 15 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top